High-Resolution Complexome Profiling by Cryoslicing BN-MS Analysis
October 15th, 2019
9.3K views
A versatile cryoslicing BN-MS protocol using a microtome is presented for high-resolution complexome profiling.
Overview
This article presents a versatile cryoslicing BN-MS protocol using a microtome for high-resolution complexome profiling. The method enables detailed analysis of protein complexes involved in signal transduction across various biological samples.
Key Study Components
Area of Science
- Neuroscience
- Biochemistry
- Proteomics
Background
- csBN-MS technique provides high-resolution analysis of native protein complexes.
- Originally developed for rodent brain, it can be adapted for other biological samples.
- Focuses on membrane proteins and their assembly in tissues.
- Involves careful preparation and handling of gel samples for optimal results.
Purpose of Study
- To enhance understanding of protein complex organization and assembly.
- To provide a detailed protocol for analyzing membrane protein assemblies.
- To extend high-resolution complexome profiling to low-abundant proteins.
Methods Used
- Preparation of linear or hyperbolic pore gradient gels.
- Ultracentrifugation for solubilization and concentration of membrane proteins.
- BN-PAGE for protein separation followed by gel slicing.
- Mass spectrometric analysis of tryptic digests from gel slices.
Main Results
- High-resolution separation of protein complexes with minimal artifacts.
- Accurate reconstruction of protein profiles based on peptide intensity.
- Assessment of gel sampling step size impacts resolution of complexes.
- Successful adaptation of the method for various biological samples.
Conclusions
- The csBN-MS protocol significantly improves complexome profiling.
- It allows for detailed analysis of membrane proteins in diverse tissues.
- Methodology can be applied to study low-abundant proteins effectively.
Frequently Asked Questions
What is the csBN-MS technique?
The csBN-MS technique is a method for analyzing protein complexes at high resolution, particularly focusing on membrane proteins.
Can this protocol be used for samples other than rodent brain?
Yes, the csBN-MS technique can be adapted for various biological samples beyond rodent brain.
What are the key steps in the csBN-MS protocol?
Key steps include gel preparation, protein solubilization, BN-PAGE, gel slicing, and mass spectrometric analysis.
How does the csBN-MS technique improve resolution?
It improves resolution by careful gel preparation and slicing, allowing for detailed analysis of protein complexes.
What types of proteins can be analyzed using this method?
The method is particularly effective for analyzing membrane proteins and low-abundant proteins.
What is the significance of the gel sampling step size?
The gel sampling step size is crucial for achieving high resolution in the separation of protein complexes.
Executive Industry Relevance
High-resolution complexome profiling addresses the critical gap in understanding membrane protein complex organization, which is essential for target validation in signal transduction pathways. By enabling unbiased detection of low-abundance membrane proteins and their assembly states, the method supports mechanistic de-risking in early discovery. This capability enhances predictive confidence for portfolio decisions involving membrane-associated targets such as ion channels and transporters.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by resolving native protein complex composition and stoichiometry.
- Operational Value: Provides functional target validation through detection of uniform, low-abundance membrane proteins like intracellular ion channels.
- Predictive Value: Supports portfolio triage by revealing complex assembly patterns and glycosylation isoforms that inform target druggability.
Screening & Assay Development
- Assay Readiness: Prepares validated biological systems for downstream workflows by delivering quantitative protein profiles from complex separations.
- Reproducibility: Ensures assay standardization through run-to-run variation correction via peak volume data rescaling.
- Scalability: Facilitates platform reuse across biological systems due to adaptability of csBN-MS to any sample type.
Translational & Preclinical Research
- Translational Continuity: Connects discovery to preclinical validation by identifying novel subunits and complex assemblies with agreement to independent biochemical analyses.
- Risk-Adjusted Advancement: Informs decisions by demonstrating fixed abundance ratios in core subunits of complexes like gamma-secretase, indicating stable targets.
- Mechanistic De-risking: Focuses on predictive value by revealing isoform-specific stoichiometries in complexes such as ferritin, reducing ambiguity in target behavior.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from hypothesis testing through lead identification to preclinical validation, particularly for membrane protein targets.
- Discovery Biology: Supports hypothesis testing and pathway clarification by resolving protein (super)complexes and their subunit composition in native states.
- Screening: Enables assay readiness through high-resolution separation with minimal migration artifacts and accurate peptide intensity reconstruction.
- Analytics: Delivers quantitative measurements and statistical outputs that allow comparison of complex populations across conditions.
- Translational Research: Connects to preclinical continuity by detecting disease-relevant complex patterns in endosome-enriched fractions.
- Enterprise Reuse: Functions as a reusable capability for complexome profiling across tissues and pathophysiological states when combined with isotope labeling.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence through comprehensive and unbiased identification of protein complexes and subunit composition.
- Operational Value: Standardization and reproducibility via controlled gel slicing and MS data rescaling.
- Strategic Value: Better go/no-go decisions by reducing mechanistic ambiguity in membrane protein target validation.
- Portfolio Impact: Risk-adjusted prioritization based on complex assembly dynamics and isoform-specific abundance.
Implementation Considerations
- Expertise in native PAGE, cryoslicing, and mass spectrometry is required for optimal complex resolution.
- Instrumentation includes gradient mixers, ultracentrifuges, BN-PAGE systems, cryoslicing microtomes, and high-resolution mass spectrometers.
- Cross-team standardization depends on consistent gel preparation, embedding alignment, and slicing plane calibration.
- Adaptation across model systems is supported by the method’s applicability to any biological sample type.
- Practical limitations include the need for careful gel handling to avoid tearing or tilting, which would compromise resolution.
Biopharma FAQs
Why does gel sampling step size matter for target validation?
The gel sampling step size directly affects the resolution of protein complex populations, as demonstrated by the ability to distinguish TPC1-associated subpopulations at 0.25 mm but not when more slices are joined. This resolution is critical for validating targets with isoform-specific assembly states.
How does BN-PAGE separation enable mechanistic de-risking in discovery?
BN-PAGE separates native protein complexes by size, allowing detection of low-abundance membrane proteins and their assembly patterns, which reduces uncertainty in target behavior and supports hypothesis testing in early discovery.
What quantitative outputs enable lead identification decisions?
Label-free protein quantification from tryptic digests of gel slices reconstructs relative abundance profiles of 2,545 proteins, providing quantitative measurements that help prioritize leads based on complex stoichiometry and isoform expression.
Why are replication requirements important for cross-functional collaboration?
Run-to-run variations are eliminated by rescaling peak volume data sets, ensuring reproducible complexome profiles that allow consistent interpretation across discovery, screening, and preclinical teams.
What statistical analysis is required before implementing csBN-MS in a workflow?
Implementation requires the ability to rescale peak volume data sets and join adjacent slice datasets to assess resolution impact, enabling accurate reconstruction of protein profiles and discrimination of complex subpopulations.
